Can a new tracer match the gold standard for heart scans?

NCT ID NCT07761728

First seen Aug 12, 2026 · Last updated Aug 17, 2026 · Updated 2 times

Summary

This trial is testing whether a new PET imaging tracer, 18F-flurpiridaz, can detect coronary artery disease as accurately as the current standard, 82Rb-chloride. The study will involve 60 adults scheduled for a clinically indicated PET scan. Researchers will compare the diagnostic performance of the two tracers using coronary CT angiography as a reference standard, potentially offering a new option for heart imaging.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
18F-flurpiridaz, a radioactive tracer used in PET imaging
What this could lead to
If 18F-flurpiridaz proves as effective as the standard tracer, it could offer a more accessible or convenient option for diagnosing coronary artery disease.
What could go wrong
This is a relatively small study, and results may not apply to all patients. The new tracer might not match the standard's accuracy, and there are always risks associated with radiation exposure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • West Los Angeles Veterans Affairs Medical Center

    Los Angeles, California, 90073, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.